Distinct outcome patterns according to RAS and BRAF status in MSI-H/dMMR mCRC treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Andrea Pretta

doi:10.1016/j.ctrv.2026.103178

Distinct outcome patterns according to RAS and BRAF status in MSI-H/dMMR mCRC treated with immune checkpoint inhibitors: A systematic review and meta-analysis

2026-06-25

0

PRE

AI

A

Andrea Pretta *

R

Riccardo Giampieri

A

Andrea Bottelli

A

Ada Taravella

R

Rossana Intini

P

Pina Ziranu

C

Carolina Liguori

F

Federica Manoni

M

Matteo Landi

G

Giulia Maddalena

G

Giorgia Locci

C

Clelia Donisi

M

Mariapaola Masiello

M

Matteo Caschili

A

Anna Bassetti

V

Valentino Pasquinucci

A

Antonio Maccioni

S

Sara Sperotto

F

Francesca Bergamo

R

Rossana Berardi

DOI：10.1016/j.ctrv.2026.103178

Original

Original request for help

Save

Abstract

En 中文

• Survival varies with RAS and BRAF mutations in MSI-H mCRC treated with ICIs. • BRAF mutation maintains poor prognosis despite similar ORR. • RAS mutation linked to modestly longer PFS. • ORR remains consistent across molecular subgroups. • Supports biomarker-based stratification in MSI-H mCRC.

Distinct outcome patterns according to RAS and BRAF status in MSI-H/dMMR mCRC treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Abstract

Journal

Organization

Cited Papers

Citing Papers